Kaya Holdings (KAYS) EBITDA Margin (2014 - 2025)
Kaya Holdings (KAYS) recorded quarterly EBITDA Margin of 4974.3% in Q3 2025, down 208.92% quarter-over-quarter from 1610.22% in Q2 2025, and up 2978444.0% on a YoY basis from N/an in Q3 2024.
Kaya Holdings (KAYS) EBITDA Margin (2014 - 2025) Analysis & Trends
Kaya Holdings' EBITDA Margin history runs 12 years deep, the most recent figure standing at 4974.3% for Q3 2025.
- In Q3 2025, EBITDA Margin rose 2978444.0% year-over-year to 4974.3%; the TTM figure through Sep 2025 stood at 86570.18% (up 8921851.0% YoY), while the FY2024 annual figure was 28343.54%, down 2782251.0% from the prior year.
- EBITDA Margin was 4974.3% for Q3 2025 at Kaya Holdings, down from 1610.22% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 1674.82% in Q4 2024 to a low of 34758.73% in Q3 2024.
- Historically, EBITDA Margin has averaged 2705.99% across 5 years, with a median of 377.56% in 2023.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin slumped 3429080 bps in 2024, then jumped 2978444 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 187.8% in 2021, then slumped by 249 bps to 655.81% in 2022, then soared by 56 bps to 287.2% in 2023, then surged by 683 bps to 1674.82% in 2024, then slumped by 397 bps to 4974.3% in 2025.
- The last three EBITDA Margin figures came in at 4974.3% (Q3 2025), 1610.22% (Q2 2025), and 4389.36% (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | -1.01% |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 22.74% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -170.35% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 21.55% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -16.25% |
| 10 | Kaya Holdings | - | - | 5,370.00 | -4,974.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -4,974.30% |
| Jun 30, 2025 | -1,610.22% |
| Mar 31, 2025 | -4,389.36% |
| Dec 31, 2024 | 1,674.82% |
| Sep 30, 2024 | -34,758.73% |
| Mar 31, 2024 | -852.69% |
| Dec 31, 2023 | -287.20% |
| Sep 30, 2023 | -467.93% |
| Jun 30, 2023 | -568.46% |
| Mar 31, 2023 | -696.19% |
| Dec 31, 2022 | -655.81% |
| Sep 30, 2022 | -156.02% |
| Jun 30, 2022 | -138.08% |
| Mar 31, 2022 | -174.35% |
| Dec 31, 2021 | -187.80% |
| Sep 30, 2021 | -221.05% |
| Jun 30, 2021 | -118.86% |
| Mar 31, 2021 | -125.51% |
| Dec 31, 2020 | -186.95% |
| Sep 30, 2020 | -279.77% |